Related Experiment Video

Updated: Apr 20, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.8K

Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations

Yiran Wu1, Xiaolong Zhuo, Ziwei Dai

  • 1BNLMS, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, and Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China. lhlai@pku.edu.cn.

Molecular Biosystems
|November 25, 2014
PubMed

Insights

Combining Aurora B and polo-like kinase 1 (PLK1) inhibitors induces polyploidy. Integrating microtubule inhibitors with PLK1 inhibitors may reduce dosage and enhance treatment tolerance in cancer therapy.

Area of Science:

  • Oncology
  • Cell Biology
  • Systems Biology

Background:

  • Targeting mitotic regulators like Aurora A/B kinase and polo-like kinase 1 (PLK1) is crucial for cancer therapy.
  • Combinations of kinase inhibitors may offer enhanced therapeutic effects over single agents.
  • A systematic analysis of combined mitotic regulator inhibitor effects is currently lacking.

Purpose of the Study:

  • To construct the first mammalian cell mitotic regulation network model.
  • To systematically explore the combined effects of kinase and microtubule inhibitors.
  • To identify novel therapeutic strategies for cancer by understanding mitotic regulation.

Main Methods:

  • Development of a comprehensive mammalian cell mitotic regulation network model.
  • Systematic in silico exploration of combined kinase and microtubule inhibitor effects.
  • Experimental validation of predicted inhibitor combination efficacies.

Main Results:

  • Simultaneous inhibition of Aurora B and PLK1 strongly induces polyploidy.
  • Combining microtubule inhibitors with PLK1 inhibitors allows for significant dosage reduction.
  • Experimental validation confirmed the efficacy of these combined inhibitor strategies.

Conclusions:

  • The developed mitotic regulatory network model serves as a platform for studying mitosis and identifying drug targets.
  • Combining microtubule inhibitors with PLK1 inhibitors is a promising strategy to enhance treatment tolerance.
  • This approach may improve therapeutic outcomes for a broad range of cancer patients.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.5K